MedTrace Logo

Irinotecan in Treating Children With Refractory or Progressive Solid Tumors

NCT00016861 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2013-06-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of irinotecan in treating children who have refractory or progressive solid tumors.

Conditions

  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

DRUG

irinotecan hydrochloride

Sponsors & Collaborators

  • Texas Children's Cancer Center

    lead OTHER

Principal Investigators

  • Susan M. Blaney, MD · Texas Children's Cancer Center

Study Design

Purpose
TREATMENT

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-09-30
Completion
2005-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00016861 on ClinicalTrials.gov